Breast Cancer Therapeutics

SUMMARY

This report analyzes the worldwide markets for Breast Cancer Therapeutics in US$ Million. The major product segments analyzed are Hormonal Therapy, Chemotherapy, and Innovative Therapy. The report provides separate comprehensive analytics for the USA, Europe and Rest of World. Annual forecasts are provided for the period of 2000 through 2010. The report profiles 102 companies including many key and niche players worldwide such as Abraxis Bioscience Inc., Aeterna Zentaris Inc., Agendia BV, Aphton Corp., Array BioPharma Inc., AstraZeneca Plc, Bristol Myers Squibb, Dendreon Corporation, Eli Lilly and Company, Genentech Inc., Genta Inc., Novartis AG, Pfizer Inc., Roche Group, Sanofi-Aventis, Schering AG, Therion Biologics Corporation, and ViRexx Medical Corp. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability And Reporting Limitations I-1
• Disclaimers I-2
• Data Interpretation & Reporting Level I-2
• Quantitative Techniques & Analytics I-3
• Product Definitions And Scope Of Study I-3

II. EXECUTIVE SUMMARY

1. Market Dynamics II-1

• Outlook & Trends II-1
• Targeted Therapies Bridge Therapeutic Gap II-1
• Significant Unmet Medical Need Drives Growth II-1
• Herceptin Makes Headway as a Breakthrough Breast Cancer Therapeutic II-2
• Aromatase Inhibitors Dethrone Tamoxifen's Gold-Standard Status II-2
• Biotechnology Makes its Presence Felts II-3
• Toxicity of Chemotherapeutic Agents In the Spotlight II-3
• Pipeline Diversity Ranging from Novel Cytotoxics to Metronomic Therapy II-4
• Advances in Screening, Testing and Diagnosis Exert Positive Impact II-4
• Fundamental Trends Fuel Demand for Quality Healthcare II-5
• Pharmaceutical Industry Faces Aggressive Pricing Regulations II-5
• An Overview of the Pharmaceutical and Oncology Markets II-5
• Pharmaceutical Industry: A Review II-5
• A Note on the Pharma Industry II-5
• 2005 in a Nutshell II-6
• Market Issues II-6
• Cost Control: A Major Hurdle II-6
• Price Controls: Companies under Pressure II-6
• United States II-7
• Europe II-7
• Japan II-7
• Cross-Border Selling: Widespread Phenomena II-7
• The Process of Approval II-7
• Competitive Landscape II-8
• A Brief Study of the Oncology Sector II-8
• Competition in the Cancer Therapeutics Market II-8
• Table 1: Share of Leading Players in the Global Cancer
• Therapeutics Market: 2000 & 2005 (includes corresponding Graph/Chart) II-9
• Market Landscape in Breast Cancer Therapeutics II-10
• Global Breast Cancer Therapeutics Market II-10
• Pharma Powerhouses Dominate Breast Cancer Therapeutics II-10
• Table 2: Global Sales of Leading Breast Cancer Drugs: 2003-2005 (US$ Million) (includes corresponding Graph/Chart) II-10
• Table 3: Global Market Share of Companies Offering Breast Cancer Therapeutics: 2004 (includes corresponding Graph/Chart) II-11
• Why do the Top Three have a Lion's Share? II-11
• Table 4: Percent Share of Global Breast Cancer Therapies by Type - Chemotherapy, Hormonals and Innovatives: 2006E (includes corresponding Graph/Chart) II-11
• Table 5: Share of Various Treatment Regimens in the Breast Cancer Market: 2001 (includes corresponding Graph/Chart) II-12
• Hormonal Therapy Segment II-12
• Global Hormonal Therapeutics II-12
• Table 6: Global Share of Hormonal Therapeutics in Breast Cancer: 2002 & 2005 (includes corresponding Graph/Chart) II-12
• Table 7: Global Aromatase Inhibitor Sales in Adjuvant and Metastatic Settings (US$ Million): 2003 II-13
• Arimidex II-13
• Table 8: Global Sales of Aromatase Inhibitor - Arimidex: 1998-2005 (US$ Million) (includes corresponding Graph/Chart) II-13
• Femara II-13
• Table 9: Global Sales of Aromatase Inhibitor - Femara: 1998 -2006 (US$ Million) (includes corresponding Graph/Chart) II-14
• Aromasin II-14
• Table 10: Global Sales of Aromatase Inhibitor - Aromasin: 2001-2006 (US$ Million) (includes corresponding Graph/Chart) II-14
• Nolvadex II-14
• Table 11: Global Sales of Tamoxifen (Nolvadex): 1997-2005 (US$ Million) (includes corresponding Graph/Chart) II-14
• Faslodex II-15
• Table 12: Global Sales of Faslodex: 2002-2005 (US$ Million) (includes corresponding Graph/Chart) II-15
• Zoladex II-15
• Table 13: Global Sales of Zoladex: 2000-2005 (US$ Million) (includes corresponding Graph/Chart) II-15
• Chemotherapy Segment II-15
• Table 14: Estimated Share of Various Chemotherapeutics in Breast Cancer: 2002 (includes corresponding Graph/Chart) II-15
• Table 15: Global Sales of Anthracyclines - Epirubicin, Doxorubicin, Idarubicin, Daunorubicin: 2002 (US$ Million) (includes corresponding Graph/Chart) II-16
• Targeted Therapy Segment II-16
• Table 16: Global Sales of Herceptin: 1999-2006 (US$ Million) (includes corresponding Graph/Chart) II-16
• Competitive Factors II-16

2. Product Overview II-17

• History in a Nutshell II-17
• Anatomy of the Breast II-17
• What is Breast Cancer? II-17
• Origin II-18
• Symptoms II-18
• Stages II-18
• Spread II-18
• Pathology II-19
• Ductal Cancer II-19
• In Situ II-19
• Invasive II-19
• Lobular Cancer II-19
• In-Situ II-19
• Invasive II-19
• Others II-19
• Inflammatory Cancer II-19
• Paget's Disease II-19
• Prognosis II-20
• Factors for Good Prognosis II-20
• Factors for Poor Prognosis II-20
• Statistics on Breast Cancer Incidence Worldwide II-20
• Terminology II-20
• Incidence Statistics: What the Numbers Mean? II-20
• Table 17: New Breast Cancer Cases Worldwide by Region/Country - Western World (US, Canada, Japan, European Union), Developing Nations and Others: 2005 (includes corresponding Graph/Chart) II-21
• Table 18: Estimated Number of New Breast Cancer Cases/Deaths Worldwide: 2000 (includes corresponding Graph/Chart) II-21
• Table 19: Age-Adjusted Death Rates in Female Breast Cancer Worldwide - by Select Countries: 2002 (Per 100,000 Population) (includes corresponding Graph/Chart) II-22
• Prevalence Patterns II-22
• Incidence Rates: Rising Worldwide II-22
• Occurrence of Male Breast Cancer II-23
• Survival: A Critical Factor II-23
• Table 20: Five-Year Survival Rate by Cancer Stages (includes corresponding Graph/Chart) II-23
• Table 21: Five-Year Survival Rate for Local, Regional and Metastasized Cancer II-23
• Risk Factors II-24
• Geographical Variances II-24
• Age II-24
• Table 22: Age and Breast Cancer Incidence II-24
• Table 23: Global Population of Women Aged 65 years and Above by Region - North America, Japan, Europe, Asia, Latin America and Rest of World: 2005E (includes corresponding Graph/Chart) II-25
• Table 24: Global Population of Women Aged 65 years and Above by Select Countries - US, Canada, Japan, France, Germany, UK, Italy, Spain, Russia, China, India, Argentina, Brazil, Mexico and South Africa (In Thousands) (includes corresponding Graph/Chart) II-25
• Reproductive Factors II-25
• Age at First Full-Term Pregnancy II-26
• Genetic Predisposition II-26
• Breast Condition II-26
• Radiation II-26
• Fat Intake II-26
• Weight or Obesity II-26
• Alcohol Consumption II-27
• Intake of Hormones II-27
• Hormone Replacement Therapy II-27
• Screening and Diagnosis II-27
• Mammography Screening II-27
• The Technique II-27
• Types II-27
• Screening Mammography II-27
• Diagnostic Mammography II-28
• Digital Mammography II-28
• Full-Field Digital Mammography II-28
• Trends in Mammography II-28
• Digital Systems Drive Market Growth II-28
• Diagnostic Investigations II-29
• Breast Self-Examination II-29
• Clinical Breast Examination II-29
• Biopsy II-29
• Needle Biopsy II-29
• Sentinel Lymph Node Biopsy II-29
• Steriotactic Needle Biopsy II-29
• Other Diagnostic Techniques II-29
• DOBI Medical's Dynamic Optical Breast Imaging (DOBI) II-29
• Hologic's 3-D Tomosynthesis II-30
• Patient Awareness & Education II-30

3. A Study Of Therapeutic Strategies II-31

• Therapy Types II-31
• A Complex Disease with Multiple Treatment Options II-31
• Flowchart of Treatment Options for Metastatic and Non-Metastatic Breast Cancer II-31
• Breast Cancer Treatments (All Types) for Various Stages II-33
• Factors that Determine Therapeutic Conduct II-33
• A Study of Various Therapy Types II-34
• Definitions and Scope II-34
• Hormonal Therapy II-34
• What is Endocrine/Hormonal Therapy? II-34
• The Biochemical Process of Sex hormones II-35
• What are the Drug Categories? II-35
• Categories of Hormonal Agents II-35
• Hormonal Therapies and their Indications II-36
• An Analysis of Hormonal Drug Classes II-36
• SERM II-36
• Mechanism of Action II-36
• Products in the Drug Class II-36
• Nolvadex (Tamoxifen) II-37
• Evista (Raloxifene) II-37
• Fareston (Toremifene) II-37
• Arzoxifene II-37
• SERD II-37
• Mechanism of Action II-37
• Products in the Drug Class II-38
• Faslodex (Fulvestrant) II-38
• Differences in ERDs and SERMs II-38
• Aromatase Inhibitors II-38
• History II-38
• Mechanism of Action II-39
• Products in the Drug Class II-39
• Arimidex (Anastrozole) II-39
• Femara (Letrozole) II-39
• Aromasin (Exemestane) II-40
• Differences Among the Trio II-40
• Costs II-40
• Table 25: Comparative Cost of Tamoxifen and Aromatase Inhibitors in the US and Europe (includes corresponding Graph/Chart) II-40
• LHRH Analogs II-41
• The Pituitary-Gonadal System II-41
• What are LHRH Analogs? II-41
• LHRH Agonists vs. Antagonists II-41
• Products in the Drug Class II-41
• Lupron (Leuprolide) II-41
• Zoladex (Goserelin Acetate) II-42
• Progestogens II-42
• Ovarian Shutdown and Removal II-42
• Target Audience II-43
• Where is it Used? II-43
• Choosing the Right Therapeutic Strategy II-43
• Side Effects II-44
• Duration of Therapy II-44
• Therapy Types II-45
• Adjuvant Hormonal Therapy II-45
• Neoadjuvant Hormonal Therapy II-45
• Metastatic Hormonal Therapy II-45
• Benefits II-45
• Advances II-45
• Comparative Study of Hormonal Therapies II-46
• Aromatase Inhibitors vis-à-vis SERMs II-46
• SERMs, Aromatase Inhibitors, and SERDs II-46
• Pivotal Clinical Trials II-47
• ATAC Trial: Arimidex, Tamoxifen Alone or in Combination II-47
• Replacing Tamoxifen with Anastrozole II-47
• Hormone Receptor Status and Endocrine Therapy II-47
• Extended Adjuvant Endocrine Therapy II-48
• Neoadjuvant Endocrine Therapy II-48
• Austrian Breast and Colorectal Cancer Study Group [ABSCG]-8/Arimidex-Nolvadex [ARNO]-95 trials II-48
• Italian Tamoxifen-Arimidex (ITA) trial II-49
• STAR: Study of Tamoxifen and Raloxifene II-49
• IBIS: International Breast Cancer Intervention Studies II-49
• IBIS I II-49
• IBIS II II-49
• IES: Intergroup Exemestane Study II-50
• MA 17 Study II-50
• BIG 1-98 II-50
• Chemotherapy II-51
• What is Chemotherapy? II-51
• Efficacy II-51
• Areas of Use II-51
• Adjuvant Setting II-52
• Neoadjuvant Setting II-52
• Metastatic Setting II-52
• Classes of Cytotoxic Agents II-52
• Cell Cycle and Effects of Cytotoxics on Various Phases II-53
• Cytotoxic Drug Classes and Mode of Action II-53
• Anthracyclines II-53
• Description II-53
• Mode of Action II-53
• Products in the Drug Class II-54
• Doxorubicin and Epirubicin II-54
• Side Effects II-54
• Mitotic Inhibitors II-54
• Description and Mechanism of Action II-54
• Current Research Activity II-55
• Taxanes & Vinca Alkaloids II-55
• Mechanism of Action - Taxanes II-55
• Products in the Drug Class II-55
• Abraxane (albumin-bound paclitaxel) II-55
• A Breakthrough Formulation II-55
• The Product and the Technology II-56
• Abraxane Eliminates Solvent Related Toxicity II-56
• How does nab T Technology Work? II-56
• Clinical Trial Data II-56
• Current Approval II-57
• Taxotere (Docetaxel) II-57
• Taxol(Paclitaxel) II-57
• Vinorelbine II-57
• Antimetabolites II-58
• Description II-58
• Mechanism of Action II-58
• Types II-58
• Purine Analogues II-58
• Folic Acid Analogues II-58
• Products in the Drug Class II-58
• Xeloda (Capecitabine) II-58
• Xeloda and Taxotere Combination Therapy II-58
• Xeloda Monotherapy II-59
• Gemzar (Gemcitabine) II-59
• New Developments II-59
• Alkylating Agents II-59
• Description II-59
• Mechanism of Action II-59
• Classes of Alkylating Agents II-60
• Nitrosoureas II-60
• Topoisomerase II Inhibitors II-61
• Other Chemotherapy Drugs II-61
• A Compilation of Various Chemotherapeutic Agents II-61
• Common Chemotherapy Regimens II-64
• Established and Emerging Regimens II-64
• CMF II-64
• TAC & FAC II-64
• CA Followed by Trastuzumab + Paclitaxel II-64
• High-Dose Chemo with Peripheral-Blood
• Stem-Cell or Bone Marrow Transplantation II-64
• Side Effects Associated with Cytotoxic Agents II-64
• Overcoming Cytotoxic Resistance II-65
• Immunotherapy II-65
• The Concept of Immunotherapy II-65
• Cancer Vaccines II-65
• Breast Cancer Vaccine Pipeline II-66
• Monoclonal Antibodies II-66
• Types of Monoclonal Antibodies II-66
• Mechanism of Action II-66
• Herceptin - A Potential Blockbuster II-66
• About HER2+Breast Cancer II-66
• Incidence of HER2+ Cases II-67
• What is Herceptin? II-67
• Herceptin its Indications II-67
• Potential for Herceptin II-67
• Where is it Indicated? II-67
• Current Areas of Indication II-67
• Use in Metastatic and Non-Metastatic Stages II-68
• For Metastatic Indication II-68
• For Non-Metastatic Disease II-68
• Mechanism of Action II-68
• Toxicity Profile II-68
• Therapy Determination Tests II-69
• IHC II-69
• FISH II-69
• Global Availability II-69
• Global and Regional Marketers II-69
• Studies Evaluating Efficacy of Herceptin II-69
• HERA Study II-69
• M77001 Study Group Trial II-70
• B-31 and N9831Clinical Trials II-70
• Novel Therapy II-70
• What are Novel Therapeutics? II-70
• Drugs Targeting Receptors/Pathways Active in Breast Cancer II-71
• Avastin - In the Wings II-71
• Product Description II-71
• Avastin and its Indications II-71
• Avastin Breast Cancer Trials II-72
• Market Issues II-72
• Disappointments Galore in the Anti-Angiogenesis Area II-72
• Growth Factor Inhibitors II-73
• ErbB-2 Inhibitors II-73
• EGFR Inhibitors II-73
• Angiogenesis Inhibitors II-73
• The Process II-73
• Drugs under Development II-73
• Lapatinib (previously GW572016) II-73
• Iressa (Gefitinib) II-73
• MEK Inhibitors/Farnesyl Transferase II-74
• Targeting Apoptosis II-74
• Antisense Technology II-74
• Targeting mTOR Pathway II-75
• Radiation Therapy II-75
• Definition II-75
• Types of Radiotherapy II-75
• Whole-Breast External Beam Radiation Therapy II-75
• Accelerated Partial Breast Irradiation Therapy II-75
• Side Effects II-76
• Notable Products II-76
• Cytokinetics' MammoSite Radiation Therapy System II-76
• Surgery II-77
• Conventional Treatment Method II-77
• Types of Surgical Procedures II-77
• Lumpectomy II-77
• Mastectomy II-77
• Table 26: Five-Year Survival Rate Based on Type of Surgery (includes corresponding Graph/Chart) II-78
• Breast Reconstruction II-78
• Palliation and Support II-78

4. Research and Development II-79

• Product Development Timeline and Clinical Stages II-79
• Pipeline Drugs (Phases I, II and III) and their Clinical Status II-80
• Tests Available or under Development II-83
• BioLabs' Mammastatin Serum Assay (MSA) II-83
• Agendia's MammaPrint Test II-83
• Matritech's Nuclear Matrix Protein (NMP66) II-83
• Power3 Medical Products' NAF Test II-83
• Genomics Health's Oncotype DX II-83
• Use of DNA Microarray with a Chemotherapeutic Agent II-84
• Novel Therapeutic Technologies II-84
• Gene Expression Profiling II-84
• Genetic Testing II-84
• Biomarkers II-84
• Types and Significance II-84
• Blood and Body Fluids as Biomarkers II-85
• Hybrid Assays II-85
• CTC Detection II-85
• Prediction of Therapeutic Response and Prognosis II-85
• Proteomics II-86

5. Focus on Select Players II-87

• Abraxis Bioscience Inc, US II-87
• Aeterna Zentaris Inc, Canada II-87
• Agendia BV, The Netherlands II-87
• Aphton Corp, US II-88
• Array BioPharma Inc, US II-88
• AstraZeneca Plc, UK II-88
• Bristol Myers Squibb, US II-88
• Dendreon Corporation, US II-88
• Eli Lilly and Company, US II-89
• Genentech Inc, US II-89
• Genta Inc, US II-89
• Novartis AG, Switzerland II-89
• Pfizer Inc, US II-90
• Roche Group, Switzerland II-90
• Sanofi-Aventis, France II-90
• Schering AG, Germany II-90
• Therion Biologics Corporation, US II-91
• ViRexx Medical Corp, Canada II-91

6. Product Launches & Approvals II-92

• EC Approves Herceptin for Early Stage Adjuvant Treatment II-92
• Novartis and Chugai Pharmaceuticals Introduce Femara in Japan II-92
• Abraxane Receives Canadian Approval for Metastatic Breast Cancer II-92
• Roche Files Marketing Authorization Application for Early-Stage Herceptin Therapy II-92
• Genentech and Roche Submit Avastin sBLA for Metastatic Breast Cancer II-92
• Abraxane Receives Approval in the US for Metastatic Breast Cancer II-93
• Femara Approved in the US for Early Adjuvant Setting II-93
• Aromasin Approved for Adjuvant Use in Early Breast Cancer II-93
• Femara Approved in UK for Early-Stage Breast Cancer II-94
• Schering Commences Three Phase 2 Clinical Trials with ZK-EPO II-94

7. Recent Industry Activity II-95

• AstraZeneca and Schering Collaborate for SERD Breast Cancer Drug II-95
• Bayer to Acquire Schering AG II-95
• AstraZeneca in Co-Promotion Agreement with Abraxis II-95
• American Pharmaceutical Partners and American BioScience Merge to Form Abraxis BioScience II-95
• AstraZeneca Acquires KuDOS Pharmaceuticals II-96
• BioMérieux and ExonHit Therapeutics in Research Collaboration II-96
• Biomedical Diagnostics Signs Up with Harlan Bioproducts for Science II-96
• bioMerieux to Use Affymetrix' GeneChip Technology in Breast Cancer Diagnostics II-96
• YM BioSciences Signs a Collaborative Agreement with Sanofi-Aventis II-96
• Genesis BioVentures and Corgenix to Merge II-97
• Celera Diagnostics Forms Research Collaboration with Merck II-97

8. Global Market Perspective II-98

• Table 27: Global Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-98
• Table 28: Global 10-Year Perspective for Breast Cancer Therapeutics by Geographic Region - US, Europe and Rest of World Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart) II-98
• Table 29: Global Recent Past, Current & Future Analysis for Breast Cancer Hormonal Therapy by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-99
• Table 30: Global 10-Year Perspective for Breast Cancer Hormonal Therapy by Geographic Region - US, Europe and Rest of World Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart) II-99
• Table 31: Global Recent Past, Current & Future Analysis for Breast Cancer Chemotherapy by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-100
• Table 32: Global 10-Year Perspective for Breast Cancer Chemotherapy by Geographic Region - US, Europe and Rest of World Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart) II-100
• Table 33: Global Recent Past, Current & Future Analysis for Breast Cancer Innovative Therapy by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-101
• Table 34: Global 10-Year Perspective for Breast Cancer Innovative Therapy by Geographic Region - US and Rest of World Markets for 2000, 2006 and 2010 II-101

III. MARKET

1. United States III-1

• A. Market Analysis III-1
• Outlook and Trends III-1
• Aromatase Inhibitors on an Upward Trajectory III-1
• Table 35: Market Share of SERMs and Aromatase Inhibitors in the US: 2005 (includes corresponding Graph/Chart) III-1
• Table 36: Market Share of Aromatase Inhibitors in the US: 2005 (includes corresponding Graph/Chart) III-2
• Immense Potential Exists for Innovatives/Targeted Therapy III-2
• Table 37: US Sales of Herceptin: 1998- 2005 (US$ Million) (includes corresponding Graph/Chart) III-2
• New Chemotherapeutic Agents Feature Reduced Toxicity III-2
• Patent Expiries Encourage Interest in Biotech Products III-3
• Growth Backed by New Product Approvals and Expanded Indications III-3
• Adjuvant Settings Emerge as a Promising Area III-3
• Patient Population III-3
• Innovative Therapy III-3
• Herceptin III-3
• Avastin III-3
• Surgery III-4
• US Market Dynamics III-4
• TNM Classification III-4
• TNM Grouping by Stage, Tumor Size, Nodal Involvement and Risk III-5
• Table 38: Percentage of Patients by Stage of Diagnosis in the US: Share by Stage - 2005 (includes corresponding Graph/Chart) III-6
• Incidence III-6
• Statistics III-7
• Table 39: Leading Types of Female Cancers in the US - % of New Cases and Deaths: 2005 (includes corresponding Graph/Chart) III-7
• Table 40: Estimated Number of New Female Breast Cancer Cases and Deaths in the US: 1997-2006E (includes corresponding Graph/Chart) III-7
• Table 41: Estimated New Female Breast Cancer Cases in Top 20 States in the US: 2000-2005 (includes corresponding Graph/Chart) III-8
• Table 42: Estimated Female Breast Cancer Deaths in Top 20 States in the US: 2000-2005 (includes corresponding Graph/Chart) III-9
• Risk Factors III-9
• High, Medium and Low Risk Factors Associated with Breast Cancer III-10
• Risk of Developing Breast Cancer: US Data III-10
• Ethnicity III-11
• Table 43: Leading Types of Cancers in African American Females - % of New Cases and Deaths: 2005E (includes corresponding Graph/Chart) III-11
• Table 44: Staged Distribution for Female Breast Cancer in African American and Whites: 1995-2000 (includes corresponding Graph/Chart) III-12
• Table 45: Female Breast Cancer Incidence and Death Rates (age-adjusted) by Race and Ethnicity, US: 1998-2002 (includes corresponding Graph/Chart) III-12
• Table 46: US-Five Year Relative Survival Ratesin African American and White Females by Stage: 1995-2000 (includes corresponding Graph/Chart) III-13
• Table 47: Leading Causes of Disease-Related Deaths Among US Hispanics: 2000 (includes corresponding Graph/Chart) III-13
• Table 48: Leading Types of Cancers in Hispanic Females - % of New Cases and Deaths: 2003E (includes corresponding Graph/Chart) III-14
• Family History III-14
• Hereditary Factors III-14
• Hormone Replacement Therapy III-15
• Breast Biopsy III-15
• Breast Radiation III-15
• Menstrual Periods III-15
• Diethylstilbestrol III-15
• Lifestyle III-15
• Breast-Feeding III-15
• Physical Activity III-16
• Genetic Testing III-16
• Other Factors III-16
• Survival Rates and its Implications III-16
• Relative Survival Rates III-16
• Table 49: Five-year Relative Survival Rates Among Female Breast Cancer Patients Based on the Number of Years Since Diagnosis (includes corresponding Graph/Chart) III-16
• Table 50: Five-year Relative Survival Rates Among Female Breast Cancer Patients Based on Age at Diagnosis (includes corresponding Graph/Chart) III-17
• Process of Therapy III-17
• A Focus on Mammography III-18
• Highest Number of Screening Procedures Worldwide III-18
• Table 51: Mammography in Women Aged 40 and Above:US (2000) III-18
• Table 52: Estimated Prices of Breast Cancer Testing Modalities in the US III-18
• Regulatory Forces Shape Mammography Fortunes III-19
• USPSTF Recommends Mammography for Women Over 40 III-19
• Competitive Dynamics of Regulatory, Prescription and Reimbursement Issues III-19
• Pharmaceutical Registration Process in the US III-19
• An Overview of Regulatory Scenario in the US III-20
• New Regulations Intensify Competitive Conditions III-21
• Prescription Conduct: Under Scrutiny III-21
• Generic Medicines Preferred to Branded Medicines III-21
• A Review of Select Medical Acts III-22
• Medicare Prescription Drug, Improvement and Modernization Act III-22
• Medicare Prescription Drug Benefit III-22
• Medicaid Program III-23
• Women's Health and Cancer Rights Act III-23
• Women's Health and Wellness Act III-23
• Mammography Quality and Standards Act III-23
• Reimbursement Issues Concerning Oncology Therapies III-23
• Male Breast Cancer III-24
• Anatomy III-24
• Symptoms III-24
• Types of Breast Cancer III-24
• Treatment III-24
• Incidence III-24
• Table 53: Estimated Number of New Male Breast Cancer Cases and Deaths: 1997-2006E (includes corresponding Graph/Chart) III-25
• Mortality and Survival III-25
• ASCO Trials III-25
• Major Breast Cancer Trials for Key Products Conducted by ASCO III-25
• B. Market Analytics III-27
• Table 54: US Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy, Chemotherapy and Innovative Therapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-27
• Table 55: US 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy, Chemotherapy and Innovative Therapy Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart) III-27

2. Europe III-28

• A. Market Analysis III-28
• Incidence III-28
• Table 56: Proportion of New Breast Cancer Cases (by Stage) in Europe At Diagnosis: 2005 (includes corresponding Graph/Chart) III-28
• Mortality and Survival III-28
• Table 57: Age-Adjusted Death Rates Per 100,000 Population Due to Female Breast Cancers in Europe - by Select Countries: 2002 (includes corresponding Graph/Chart) III-29
• Demographics III-29
• Table 58: Population of Women Aged 65 years and Above by Country - Russia, Germany, Italy, France, UK, Spain, Poland, The Netherlands, Belgium, Hungary, Czech Republic, Sweden, Austria, Switzerland, Finland, Denmark and Norway: 2005E (In Thousands) (includes corresponding Graph/Chart) III-29
• Screening and Diagnosis III-30
• Reimbursement of Mammography Procedures III-30
• Market Trends III-30
• Rapid Uptake of Aromatase Inhibitors III-30
• Chemotherapy Targets Hormone Negative Cancers III-30
• Innovative/Targeted therapy: Still on the Fringes III-31
• Market Structure III-31
• Table 59: Market Share of Companies in the European Hormonals Segment: 2002 (In terms of Sales) (includes corresponding Graph/Chart) III-31
• Table 60: Market Share of Companies in the European Chemotherapy Segment: 2002 (In terms of Sales) (includes corresponding Graph/Chart) III-31
• Opportunities and Challenges Presented by the Therapeutics Market III-32
• Pharmaceutical Registration Process in Europe III-32
• Mutual Recognition Procedure III-32
• Centralized Procedure III-32
• Reimbursement Scenario III-33
• Aggressive Efforts Underway to Control Healthcare Costs III-33
• B. Market Analytics III-34
• Table 61: European Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region -France, Germany, Italy, UK, Spain & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-34
• Table 62: European 10-Year Perspective for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain & Rest of Europe Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart) III-34
• Table 63: European Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-35
• Table 64: European 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-35

2a. France III-36

• A. Market Analysis III-36
• Highlights III-36
• Market Structure III-36
• Table 65: Market Share of Companies in the French Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart) III-36
• Table 66: Market Share of Companies in the French Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart) III-36
• Regulatory Structure III-37
• B. Market Analytics III-38
• Table 67: French Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-38
• Table 68: French 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-38

2b. Germany III-39

• A. Market Analysis III-39
• Snapshots III-39
• Market Share Data III-39
• Table 69: Share of Companies in the German Breast Cancer Therapeutics Market: 2002 (includes corresponding Graph/Chart) III-39
• Table 70: Market Share of Companies in the German Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart) III-39
• Table 71: Market Share of Companies in the German Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart) III-40
• Regulatory Scenario III-40
• B. Market Analytics III-41
• Table 72: German Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-41
• Table 73: German 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-41

2c. United Kingdom III-42

• A. Market Analysis III-42
• Highlights III-42
• Epidemiological Data III-43
• Table 74: Number of Female New Breast Cancer Cases and Deaths in the UK: 1993-2002 (includes corresponding Graph/Chart) III-43
• Table 75: Most Common Female Cancers in the UK: 2002 (includes corresponding Graph/Chart) III-43
• Table 76: Number of New Female Breast Cancer Cases Diagnosed in the UK: 2000 (includes corresponding Graph/Chart) III-44
• Table 77: Number of Female Breast Cancer Deaths in the UK: 2002 (includes corresponding Graph/Chart) III-44
• Issues & Trends III-45
• Aromatase Inhibitors: On the Recommendation List III-45
• Massive Government Efforts to Enhance Breast Cancer Awareness III-45
• Implementation of the National Screening Program III-45
• Reimbursement and Regulatory Environment III-45
• Competition III-46
• Table 78: Market Share of Companies in the UK Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart) III-46
• Table 79: Market Share of Companies in the UK Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart) III-46
• B. Market Analytics III-47
• Table 80: UK Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-47
• Table 81: UK 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-47

2d. Italy III-48

• A. Market Analysis III-48
• Market Snippets III-48
• Competitive Framework III-48
• Table 82: Market Share of Companies in the Italian Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart) III-48
• Table 83: Market Share of Companies in the Italian Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart) III-48
• Regulatory Scenario III-49
• B. Market Analytics III-50
• Table 84: Italian Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-50
• Table 85: Italian 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-50

2e. Spain III-51

• A. Market Analysis III-51
• Snapshots III-51
• Market Participants III-51
• Table 86: Share of Companies in the Spanish Breast Cancer Therapeutics Market: 2002 (includes corresponding Graph/Chart) III-51
• Table 87: Market Share of Companies in the Spanish Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart) III-51
• Table 88: Market Share of Companies in the Spanish Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart) III-52
• Regulatory Scenario III-52
• B. Market Analytics III-53
• Table 89: Spanish Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-53
• Table 90: Spanish 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-53

2f. Rest of Europe III-54

• A. Market Analysis III-54
• Highlights III-54
• B. Market Analytics III-54
• Table 91: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-54
• Table 92: Rest of Europe 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010 III-55

3. Rest of World III-56

• A. Market Analysis III-56
• Outlook III-56
• Focus on Select Regions III-56
• Canada III-56
• Highlights III-56
• Table 93: Breast Cancer Incidence in Canada by Age Group: 2006E III-57
• Table 94: Breast Cancer Mortality in Canada by Age Group: 2006E (includes corresponding Graph/Chart) III-57
• Table 95: Breast Cancer Incidence and Mortality in Canada by Age Group: 2005 (includes corresponding Graph/Chart) III-57
• Table 96: New Cases of Breast Cancer in Canada, By Age Group: 2004 (includes corresponding Graph/Chart) III-58
• Table 97: Breast Cancer Deaths in Canada by Age Group: 2004 (includes corresponding Graph/Chart) III-58
• Japan III-58
• Incidence III-58
• Regulatory Environment III-58
• An Overview III-58
• Expedited Approval for Marketed/Approved US and European Products III-59
• Reimbursement and Pricing Issues III-59
• Pharmaceutical Registration Process in Japan III-59
• Key Player III-60
• Chugai Pharmaceutical Co III-60
• Asia III-60
• Demographics III-60
• Table 98: Population of Women Aged 65 years and Above in Select Asian Countries - China, India, Indonesia, Thailand, South Korea, Australia and Taiwan:2005E (includes corresponding Graph/Chart) III-60
• Table 99: Population of Women Aged 65 years and Above in Latin America - Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela: 2005E (includes corresponding Graph/Chart) III-61
• Table 100: Age-Adjusted Death Rates Per 100,000 Population Due to Female Breast Cancers in anada, Japan, Asia and Latin American Countries: 2002 (includes corresponding Graph/Chart) III-61
• Australia III-61
• China III-62
• Highlights III-62
• Market Size III-62
• Table 101: Chinese Market for Breast Cancer Therapeutics with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) III-62
• India III-63
• Latin America III-63
• Ukraine III-63
• B. Market Analytics III-64
• Table 102: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Therapeutics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-64

IV. COMPETITION

• 1. 3M Pharmaceuticals (USA) IV-1
• 2. Abbott Laboratories (USA) IV-2
• Table 103: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-4
• Table 104: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-4
• Table 105: Half Yearly Sales Analysis by Segment: 2005-2006 (In US$ million) IV-4
• Table 106: Annual Sales Analysis: 2003-2005 (In US$ million) IV-5
• Table 107: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-5
• Table 108: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-5
• Table 109: Annual sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-5
• 3. Abraxis Bioscience, Inc. (USA) IV-14
• Table 110: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-15
• Table 111: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million) IV-15
• Table 112: Annual Sales Analysis: 2004-2005 (In US$ million) IV-15
• Abraxis Pharmaceutical Products (USA) IV-19
• 4. Acceptys, Inc. (USA) IV-20
• 5. Adherex Technologies, Inc. (USA) IV-21
• 6. Aeterna Zentaris, Inc. (Canada) IV-23
• Table 113: Annual Sales Analysis: 2003-2005 (In US$ million) IV-23
• Table 114: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-24
• Table 115: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-24
• Table 116: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-24
• 7. Agendia BV ( The Netherlands) IV-26
• 8. Alfacell Corporation (USA) IV-27
• 9. AlphaVax, Inc. (USA) IV-29
• 10. Amgen, Inc. (USA) IV-30
• Table 117: Half Yearly Sales Analysis: 2005-2006 (In US$ million) IV-31
• Table 118: Half Yearly Sales Analysis by Segment: 2005-2006 (In US$ million) IV-31
• Table 119: Annual Sales Analysis: 2004-2005 (In US$ million) IV-31
• Table 120: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-31
• Table 121: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-31
• 11. AnorMed, Inc. (Canada) IV-34
• Table 122: Annual Sales Analysis: 2004-2006 (In Can$ million) IV-34
• 12. Antigenics, Inc. (USA) IV-36
• Table 123: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-37
• Table 124: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-37
• Table 125: Annual Sales Analysis: 2003-2005 (In US$ million) IV-37
• 13. Antisoma PLC (UK) IV-40
• 14. Aphton Corporation (USA) IV-41
• 15. Arimidex (USA) IV-44
• 16. ARIUS Research, Inc. (Canada) IV-45
• Table 126: Annual Sales Analysis: 2004-2005 (In Can$ million) IV-45
• 17. Array BioPharma, Inc. (USA) IV-47
• 18. Astellas Pharma US, Inc. (USA) IV-49
• 19. AstraZeneca PLC (UK) IV-51
• Table 127: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-53
• Table 128: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-53
• Table 129: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million) IV-54
• Table 130: Annual Sales Analysis: 2003-2005 (In US$ million) IV-54
• Table 131: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-54
• Table 132: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-54
• 20. Bavarian Nordic (Denmark) IV-64
• Table 133: Half Yearly Sales Analysis: 2006-2005 (H1) (In DKK million) IV-65
• Table 134: Annual Sales Analysis: 2004-2005 (In DKK million) IV-65
• 21. Bayer HealthCare AG (Germany) IV-66
• Table 135: Annual Sales Analysis: 2004-2005 (In € million) IV-68
• Table 136: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-68
• Table 137: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-68
• 22. Biomira, Inc. (Canada) IV-72
• 23. Bionomics Ltd. (Australia) IV-73
• Table 138: Annual Sales Analysis: 2005-2006 (In A$ million) IV-74
• Table 139: Annual Sales Analysis by Geographic Region:2005-2006 (In A$ million) IV-74
• 24. Boehringer Ingelheim GmbH (Germany) IV-76
• Boehringer Ingelheim Pharmaceuticals, Inc. (USA) IV-80
• 25. Bristol-Myers Squibb Company (USA) IV-81
• Table 140: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-83
• Table 141: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion) IV-83
• Table 142: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion) IV-83
• Table 143: Annual Sales Analysis: 2003-2005 (In US$ billion) IV-83
• Table 144: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion) IV-83
• Table 145: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-84
• Table 146: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-84
• 26. Celgene Corporation (USA) IV-89
• Table 147: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-90
• Table 148: Annual Sales Analysis: 2004-2005 (In US$ million) IV-90
• Table 149: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-90
• Table 150: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-90
• Table 151: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-91
• 27. Cell Genesys, Inc. (USA) IV-94
• Table 152: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-95
• Table 153: Annual Sales Analysis: 2004-2005 (In US$ million) IV-95
• Table 154: Annual Sales Analysis by Operation: 2004-2005 (In US$ million) IV-95
• 28. Cell Therapeutics, Inc. (USA) IV-99
• Table 155: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-100
• Table 156: Annual Sales Analysis: 2004-2005 (In US$ million) IV-100
• Table 157: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-100
• Table 158: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-101
• 29. ChemGenex Pharmaceuticals Ltd. (Australia) IV-104
• Table 159: Annual Sales Analysis: 2004-2005 (In US$ million) IV-105
• 30. Coley Pharmaceutical Group, Inc. (USA) IV-106
• Table 160: Half Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousand) IV-106
• Table 161: Annual Sales Analysis: 2004-2005 (In Can$ thousand) IV-107
• Table 162: Quarterly Sales Analysis: 2004-2005 (In Can$ thousand) IV-107
• 31. Conforma Laboratories, Inc. (USA) IV-108
• 32. Cyclacel Pharmaceuticals, Inc. (USA) IV-108
• 33. Dendreon Corporation (USA) IV-109
• Table 163: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-109
• Table 164: Annual Sales Analysis: 2004-2005 (In US$ million) IV-109
• Table 165: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-110
• 34. Eisai, Inc. (USA) IV-111
• 35. Elan Corporation PLC (Ireland) IV-112
• Table 166: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-113
• Table 167: Annual Sales Analysis: 2004-2005 (In US$ million) IV-113
• Table 168: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-113
• Table 169: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-113
• 36. Eli Lilly & Company (USA) IV-116
• Table 170: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million) IV-118
• Table 171: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million) IV-118
• Table 172: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million) IV-118
• 37. Entremed, Inc. (USA) IV-125
• Table 173: Annual Sales Analysis: 2004-2005 (In US$ million) IV-126
• Table 174: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-126
• 38. Exonhit Therapeutics SA (France) IV-127
• 39. F. Hoffmann-La Roche Ltd. (Switzerland) IV-129
• Table 175: First Quarter Sales Analysis: 2005-2006 (In CHF billion) IV-130
• Table 176: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion) IV-130
• Table 177: Annual Sales Analysis: 2003-2005 (In CHF billion) IV-130
• Hoffmann-La Roche, Inc. (USA) IV-133
• Chugai Pharmaceutical Co., Ltd. (Japan) IV-136
• Table 178: First Quarter Sales Analysis: 2005-2006 (In ¥ million) IV-137
• Table 179: Annual Sales Analysis: 2004-2005 (In ¥ million) (Switzerland)) IV-137
• 40. Faslodex (USA) IV-140
• 41. Femara (USA) IV-140
• 42. Gemin X Biotechnologies, Inc. (Canada) IV-141
• 43. Genentech, Inc. (USA) IV-142
• Table 180: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-144
• Table 181: Annual Sales Analysis: 2004-2005 (In US$ million) IV-144
• Table 182: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-144
• 44. Generex Biotechnology Corporation (Canada) IV-149
• Table 183: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, April) (In Can$ thousands) IV-150
• Table 184: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, April) (In Can$ thousands) IV-150
• Table 185: Annual Sales Analysis: 2004-2005 (In Can$ thousands) IV-150
• Table 186: Annual Sales Analysis by Quarter: 2004-2005 (In Can$ thousands) IV-150
• 45. Genta, Inc. (USA) IV-153
• Table 187: Annual Sales Analysis: 2004-2005 (In US$ million) IV-154
• Table 188: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-154
• 46. Genzyme Corporation (USA) IV-155
• Table 189: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-158
• Table 190: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-158
• Table 191: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-159
• Table 192: Annual Sales Analysis: 2004-2005 (In US$ million) IV-159
• Table 193: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-159
• Table 194: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-159
• Table 195: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-160
• 47. Gilead Sciences (USA) IV-165
• Table 196: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In USS$ million) IV-166
• Table 197: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million) IV-166
• Table 198: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-166
• Table 199: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-167
• 48. GlaxoSmithKline PLC (UK) IV-172
• Table 200: Annual Sales Analysis: 2003-2005 (In £ million) IV-173
• Table 201: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-173
• Corixa Corporation (USA) IV-181
• 49. ImmunoGen, Inc. (USA) IV-182
• Table 202: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-182
• Table 203: Annual Sales Analysis: 2003-2005 (In US$ million) IV-183
• Table 204: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-183
• Table 205: Annual sales Analysis by Segment: 2004-2005 (In US$ million) IV-183
• 50. Immunomedics, Inc. (USA) IV-185
• Table 206: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million) IV-186
• Table 207: Nine Months Ended Sales Analysis: 2005-2006(Nine Months Ended, March) (In US$ million) IV-186
• Table 208: Annual Sales Analysis: 2004-2005 (In US$ million) IV-186
• Table 209: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-186
• 51. Immusol, Inc. (USA) IV-188
• 52. Incyte Corporation (USA) IV-190
• Table 210: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-191
• Table 211: Annual Sales Analysis: 2004-2005 (In US$ million) IV-191
• Table 212: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-191
• 53. Innovata PLC (UK) IV-193
• 54. Inovio Biomedical Corporation (USA) IV-195
• Table 213: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-195
• Table 214: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-196
• Table 215: Annual Sales Analysis: 2003-2005 (In US$ million) IV-196
• Table 216: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-196
• 55. Intarcia Therapeutics, Inc. (USA) IV-200
• 56. Introgen Therapeutics, Inc. (USA) IV-201
• Table 217: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-202
• Table 218: Annual Sales Analysis: 2003-2005 (In US$ million) IV-202
• 57. Isis Pharmaceuticals, Inc. (USA) IV-205
• Table 219: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-205
• Table 220: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-206
• Table 221: Annual Sales Analysis: 2004-2005 (In US$ million) IV-206
• Table 222: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-206
• Table 223: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-206
• 58. Janssen LP (USA) IV-209
• 59. Johnson & Johnson Pharmaceutical Research & Development LLC (USA) IV-210
• 60. Keryx Biopharmaceuticals, Inc. (USA) IV-211
• Table 224: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-212
• Table 225: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-212
• Table 226: Annual Sales Analysis: 2004-2005 (In US$ million) IV-212
• 61. Kosan Biosciences (USA) IV-214
• Table 227: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-214
• Table 228: Annual Sales Analysis: 2004-2005 (In US$ million) IV-215
• Table 229: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-215
• 62. Ligand Pharmaceuticals, Inc. (USA) IV-216
• Table 230: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-217
• Table 231: Annual Sales Analysis: 2003-2005 (In US$ million) IV-217
• 63. Medarex, Inc. (USA) IV-218
• Table 232: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-219
• Table 233: Annual Sales Analysis: 2003-2005 (In US$ million) IV-219
• Table 234: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-219
• 64. Merck & Co., Inc. (USA) IV-223
• Table 235: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-224
• Table 236: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-224
• Table 237: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million) IV-224
• Table 238: Annual Sales Analysis: 2004-2005 (In US$ million) IV-225
• Table 239: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-225
• Table 240: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-225
• Table 241: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-226
• 65. Millennium Pharmaceuticals, Inc. (USA) IV-230
• Table 242: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-230
• Table 243: Annual Sales Analysis: 2004-2005 (In US$ million) IV-230
• Table 244: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-231
• 66. Nemod Biotherapeutics GmbH & Co., KG. (Germany) IV-233
• 67. Neurocrine Biosciences (USA) IV-235
• Table 245: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-235
• Table 246: Annual Sales Analysis: 2004-2005 (In US$ million) IV-236
• Table 247: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-236
• 68. Novartis AG (Switzerland) IV-237
• Table 248: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-240
• Table 249: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-241
• Table 250: Annual Sales Analysis: 2003-2005 (In US$ million) IV-241
• Table 251: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-241
• Table 252: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-241
• Chiron Corporation (USA) IV-250
• Table 253: Annual Sales Analysis: 2003-2005 (In US$ million) IV-252
• Table 254: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-252
• Table 255: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-252
• Table 256: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-252
• Novartis Pharmaceuticals Corporation (USA) IV-257
• 69. Novo Nordisk A/S (Denmark) IV-261
• Table 257: Annual Sales Analysis: 2003-2005 (In DKK million) IV-262
• Table 258: Annual Sales Analysis by Segment: 2004-2005 (In DKK million) IV-262
• Table 259: Annual Sales Analysis by Geographic Segment: 2004-2005 (In DKK million) IV-262
• 70. Novogen Limited (Australia) IV-268
• Table 260: Annual Sales Analysis: 2004-2005 (In A$ million) IV-268
• Table 261: Annual Sales Analysis by Segment: 2004-2005 (In A$ million) IV-268
• 71. Orion Corporation (Finland) IV-269
• 72. Ortho Biotech Products LP (USA) IV-272
• 73. OSI Pharmaceuticals (USA) IV-274
• Table 262: Half Yearly Sales Analysis: 2005-2006 (In US$ million) IV-275
• Table 263: Annual Sales Analysis: 2004-2005 (In US$ million) IV-275
• 74. Oxford Biomedica PLC (UK) IV-278
• Table 264: Annual Sales Analysis: 2004-2005 (In £ million) IV-278
• 75. Oxigene, Inc. (USA) IV-282
• 76. Peregrine Pharmaceuticals, Inc. (USA) IV-284
• Table 265: Annual Sales Analysis: 2004-2006 (In US$ million) IV-284
• Table 266: Annual Sales Analysis by Segment: 2005-2006 (In US$ million) IV-285
• Table 267: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million) IV-285
• Table 268: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-285
• 77. Pfizer, Inc. (USA) IV-287
• Table 269: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-289
• Table 270: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion) IV-289
• Table 271: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-290
• Table 272: Annual Sales Analysis: 2003-2005 (In US$ billion) IV-290
• 78. PharmaMar SA (Spain) IV-294
• Table 273: Annual Sales Analysis: 2004-2005 (In € million) IV-294
• 79. Pharmexa A/S (Denmark) IV-296
• Table 274: Half Yearly Sales Analysis: 2005-2006 (H1) (In DKK million) IV-296
• 80. Phosphagenics Limited (Australia) IV-301
• 81. Pierre Fabre Médicament (France) IV-303
• 82. Procter & Gamble Pharmaceuticals (USA) IV-304
• 83. Protein Design Labs, Inc. (USA) IV-307
• Table 275: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-308
• Table 276: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-309
• Table 277: Annual Sales Analysis: 2003-2005 (In US$ million) IV-309
• 84. QLT, Inc. (Canada) IV-312
• Table 278: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-312
• Table 279: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million) IV-313
• Table 280: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million) IV-313
• 85. Sanofi-Aventis (France) IV-316
• Table 281: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-317
• Table 282: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million) IV-317
• Table 283: Annual Sales Analysis: 2004-2005 (In € million) IV-317
• Table 284: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-317
• Table 285: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-318
• Sanofi-Aventis (USA) IV-323
• 86. Schering AG (Germany) IV-325
• Table 286: First Quarter Sales Analysis: 2005-2006 (In € billion) IV-326
• Table 287: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion) IV-326
• Table 288: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion) IV-327
• Table 289: Annual Sales Analysis: 2003-2005 (In € billion) IV-327
• Table 290: Annual Sales Analysis by Segment: 2004-2005 (In € billion) IV-327
• Table 291: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion) IV-327
• Berlex Laboratories, Inc. (USA) IV-332
• Schering-Plough Corporation (USA) IV-335
• Table 292: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-336
• Table 293: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-336
• Table 294: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-336
• Table 295: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-337
• 87. Sciclone Pharmaceuticals, Inc. (USA) IV-340
• Table 296: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-340
• Table 297: Annual Sales Analysis: 2004-2005 (In US$ million) IV-341
• 88. Serono, Inc. (USA) IV-342
• Table 298: Annual Sales Analysis: 2003-2005 (In US$ million) IV-342
• 89. Solvay Pharmaceutical, Inc. (USA) IV-346
• 90. SR Pharma PLC (UK) IV-350
• Table 299: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ thousand) IV-351
• Table 300: Annual Sales Analysis: 2004-2005 (In £ thousand) IV-351
• Table 301: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ thousand) IV-351
• 91. Taiho Pharmaceutical Co. (Japan) IV-353
• 92. Targeted Genetics Corporation (USA) IV-355
• Table 302: Half Yearly Sales Analysis: 2005-2006 (In US$ million) IV-355
• Table 303: Annual Sales Analysis: 2003-2005 (In US$ million) IV-356
• 93. Telik, Inc. (USA) IV-358
• 94. Teva Pharmaceuticals (USA) IV-360
• 95. Therion Biologics Corporation (USA) IV-361
• 96. Transgene SA (France) IV-362
• Table 304: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-362
• Table 305: Annual Sales Analysis: 2004-2005 (In € million) IV-362
• 97. Vion Pharmaceuticals (USA) IV-364
• 98. ViRexx Medical Corporation (Canada) IV-365
• 99. Viventia Biotech, Inc. (Canada) IV-367
• 100. Wyeth (USA) IV-368
• Table 306: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-370
• Table 307: Half Yearly Sales Analysis by Segment: 2006-2005 (H1) (In US$ billion) IV-370
• Table 308: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-370
• Table 309: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-370
• Table 310: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-370
• 101. Xenova Group PLC (UK) IV-375
• 102. YM Biosciences, Inc. (Canada) IV-378
• Table 311: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In Can$ million) IV-378
• Table 312: Annual Sales Analysis: 2004-2005 (In Can$ million) IV-378